Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

References

• Emmi G, Silvestri E, Squatrito D, et al. Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med. 2014;9(3):257–265.
   PubMed Web of Science ®Google Scholar
• Generali E, Cantarini L, Selmi C. Ocular involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol. 2015;49(3):263–270.
   PubMed Web of Science ®Google Scholar
• Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–1582.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1147–1152.
   PubMed Web of Science ®Google Scholar
• Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):709–714.
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, et al. Ocular Behçet’s disease research group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130(5):592–598.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Orlando I, et al. Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study. Intern Emerg Med. 2017; [ [Epub ahead of print]]. doi:10.1007/s11739-017-1691-z.
   Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR expert committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656–1662.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(10):785–96.e3.
   PubMed Web of Science ®Google Scholar
• Vitale A, Emmi G, Lopalco G, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease. Clin Rheumatol. 2017; [ Epub ahead of print]. doi: 10.1007/s10067-017-3627-4.
   Web of Science ®Google Scholar
• Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol. 2017;36(2):451–455.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–189.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593–597.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95(9):1245–1250.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94(3):284–288.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161–1164.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146(6):845–50.e1.
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol Int. 2008;29(1):53–57.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye (Lond). 2014;28(9):1100–1106.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Efficacy of infliximab for early remission induction in refractory Uveoretinitis associated with Behçet disease: A 2-year follow-up study. Ocul Immunol Inflamm. 2017;25(1):46–51.
   PubMed Web of Science ®Google Scholar
• Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s disease. Lancet. 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Abdollahi BS, Chams-Davatchi C, et al. Validation of the revised International Criteria for Behcet’s Disease (ICBD) in Iran. Clin Rheumatol. 2015;34(2):315–320.
   PubMed Web of Science ®Google Scholar
• Neves FS, Moraes JC, Kowalski SC, et al. Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol. 2007;26(8):1263–1267.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Talarico R, Generali E, et al. Safety profile of biologic agents for Behçet’s disease in a multicenter observational cohort study. Int J Rheum Dis. 2017;20(1):103–108.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. French Uveitis network. Infliximab versus adalimumab in the treatment of refractory inflammatory Uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522–1530.
   PubMed Web of Science ®Google Scholar
• Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish arthritis treatment group register. Rheumatology (Oxford). 2008;47:507–513.
   PubMed Web of Science ®Google Scholar
• Gulyas K, Bodnar N, Nagy Z, et al. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis. Eur J Health Econ. 2014;15:S93–100.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102(2):317–321.
   PubMed Web of Science ®Google Scholar
• Kang EH, Park JW, Park C, et al. Genetic and non-genetic factors affecting the visual outcome of ocular Behcet’s disease. Hum Immunol. 2013;74(10):1363–1367.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60–76.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18(3):226–232.
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford). 2012;51(10):1825–1831.
   PubMed Web of Science ®Google Scholar
• Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58–62.
   PubMed Web of Science ®Google Scholar